Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy
(1) Background: The role of radiotherapy (RT) in superficial esophageal squamous cell cancer (ESCC) remains unclear. The objective of our study was to perform a detailed outcome and safety analysis of RT as a definitive or adjuvant treatment for T1N0M0 staged ESCC patients. (2) Methods: A total of 5...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/14/3423 |
| _version_ | 1797407128820908032 |
|---|---|
| author | Bo Lyu Yutian Yin Yilin Zhao Xu Yang Jie Gong Mai Zhang Guangjin Chai Zhaohui Li Mei Shi Zhouguang Hui Lina Zhao |
| author_facet | Bo Lyu Yutian Yin Yilin Zhao Xu Yang Jie Gong Mai Zhang Guangjin Chai Zhaohui Li Mei Shi Zhouguang Hui Lina Zhao |
| author_sort | Bo Lyu |
| collection | DOAJ |
| description | (1) Background: The role of radiotherapy (RT) in superficial esophageal squamous cell cancer (ESCC) remains unclear. The objective of our study was to perform a detailed outcome and safety analysis of RT as a definitive or adjuvant treatment for T1N0M0 staged ESCC patients. (2) Methods: A total of 55 patients treated with endoscopic resection (ER) + RT/concurrent chemoradiotherapy (CCRT) or RT/CCRT from January 2011 to June 2021 were included in this study. Eighteen patients with risk factors received ER + RT/CCRT, and thirty-seven patients solely received RT/CCRT. Kaplan–Meier curves were used to calculate the clinical outcomes, and toxicities were scored. (3) Results: The median follow-up time was 51.9 months. The estimated 5-year local recurrence-free survival (LRFS) and overall survival (OS) were 88.9% and 94.4% in the ER + RT/CCRT group and 91.8% and 91.7% in the RT/CCRT group. The predominant failure pattern was in-field local failure (5.5%, 3/55), with one patient in the ER + RT/CCRT group and two patients in the RT/CCRT group. One patient (1.8%, 1/55) had lung metastasis in the RT/CCRT group. The most common toxicities were Grades 1–2 in all patients, including esophagitis (74.5%, 41/55), myelosuppression (49.1%, 27/55) and esophageal stricture after RT (27.3%, 15/55). Two patients (11.1%, 2/18) and four patients (10.8%, 4/37) had Grade 3 esophageal stricture after RT in the ER + RT/CCRT group and RT/CCRT group, respectively. No patients experienced a Grade 4 or higher toxicity, and there were no treatment-related deaths. (4) Conclusions: Definitive or adjuvant RT/CCRT is an effective treatment alternative for superficial ESCC patients with satisfactory clinical outcomes and acceptable toxicities. |
| first_indexed | 2024-03-09T03:36:48Z |
| format | Article |
| id | doaj.art-c003754ab25a4de5bca4a86ce504b7e7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T03:36:48Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c003754ab25a4de5bca4a86ce504b7e72023-12-03T14:47:37ZengMDPI AGCancers2072-66942022-07-011414342310.3390/cancers14143423Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant RadiotherapyBo Lyu0Yutian Yin1Yilin Zhao2Xu Yang3Jie Gong4Mai Zhang5Guangjin Chai6Zhaohui Li7Mei Shi8Zhouguang Hui9Lina Zhao10Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, ChinaDepartment of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100000, ChinaDepartment of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710000, China(1) Background: The role of radiotherapy (RT) in superficial esophageal squamous cell cancer (ESCC) remains unclear. The objective of our study was to perform a detailed outcome and safety analysis of RT as a definitive or adjuvant treatment for T1N0M0 staged ESCC patients. (2) Methods: A total of 55 patients treated with endoscopic resection (ER) + RT/concurrent chemoradiotherapy (CCRT) or RT/CCRT from January 2011 to June 2021 were included in this study. Eighteen patients with risk factors received ER + RT/CCRT, and thirty-seven patients solely received RT/CCRT. Kaplan–Meier curves were used to calculate the clinical outcomes, and toxicities were scored. (3) Results: The median follow-up time was 51.9 months. The estimated 5-year local recurrence-free survival (LRFS) and overall survival (OS) were 88.9% and 94.4% in the ER + RT/CCRT group and 91.8% and 91.7% in the RT/CCRT group. The predominant failure pattern was in-field local failure (5.5%, 3/55), with one patient in the ER + RT/CCRT group and two patients in the RT/CCRT group. One patient (1.8%, 1/55) had lung metastasis in the RT/CCRT group. The most common toxicities were Grades 1–2 in all patients, including esophagitis (74.5%, 41/55), myelosuppression (49.1%, 27/55) and esophageal stricture after RT (27.3%, 15/55). Two patients (11.1%, 2/18) and four patients (10.8%, 4/37) had Grade 3 esophageal stricture after RT in the ER + RT/CCRT group and RT/CCRT group, respectively. No patients experienced a Grade 4 or higher toxicity, and there were no treatment-related deaths. (4) Conclusions: Definitive or adjuvant RT/CCRT is an effective treatment alternative for superficial ESCC patients with satisfactory clinical outcomes and acceptable toxicities.https://www.mdpi.com/2072-6694/14/14/3423superficial esophageal cancerradiotherapyoutcomes researchtoxicities |
| spellingShingle | Bo Lyu Yutian Yin Yilin Zhao Xu Yang Jie Gong Mai Zhang Guangjin Chai Zhaohui Li Mei Shi Zhouguang Hui Lina Zhao Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy Cancers superficial esophageal cancer radiotherapy outcomes research toxicities |
| title | Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy |
| title_full | Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy |
| title_fullStr | Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy |
| title_full_unstemmed | Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy |
| title_short | Long-Term Clinical Outcomes and Safety Analysis of Superficial Esophageal Cancer Patients Treated with Definitive or Adjuvant Radiotherapy |
| title_sort | long term clinical outcomes and safety analysis of superficial esophageal cancer patients treated with definitive or adjuvant radiotherapy |
| topic | superficial esophageal cancer radiotherapy outcomes research toxicities |
| url | https://www.mdpi.com/2072-6694/14/14/3423 |
| work_keys_str_mv | AT bolyu longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT yutianyin longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT yilinzhao longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT xuyang longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT jiegong longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT maizhang longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT guangjinchai longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT zhaohuili longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT meishi longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT zhouguanghui longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy AT linazhao longtermclinicaloutcomesandsafetyanalysisofsuperficialesophagealcancerpatientstreatedwithdefinitiveoradjuvantradiotherapy |